JPH11513562A - 組換えプラスミドの生産方法 - Google Patents
組換えプラスミドの生産方法Info
- Publication number
- JPH11513562A JPH11513562A JP9515377A JP51537797A JPH11513562A JP H11513562 A JPH11513562 A JP H11513562A JP 9515377 A JP9515377 A JP 9515377A JP 51537797 A JP51537797 A JP 51537797A JP H11513562 A JPH11513562 A JP H11513562A
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- cells
- cell
- gene
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 243
- 238000004519 manufacturing process Methods 0.000 title claims description 40
- 210000004027 cell Anatomy 0.000 claims abstract description 218
- 230000001580 bacterial effect Effects 0.000 claims abstract description 169
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 129
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 36
- 210000000349 chromosome Anatomy 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 23
- 241000206602 Eukaryota Species 0.000 claims abstract description 17
- 239000002207 metabolite Substances 0.000 claims abstract description 17
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 15
- 231100000331 toxic Toxicity 0.000 claims abstract description 14
- 230000002588 toxic effect Effects 0.000 claims abstract description 14
- 108020004414 DNA Proteins 0.000 claims description 107
- 101150102210 murF gene Proteins 0.000 claims description 75
- 102000004190 Enzymes Human genes 0.000 claims description 58
- 108090000790 Enzymes Proteins 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 43
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 29
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 29
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 23
- 101150004979 flmA gene Proteins 0.000 claims description 23
- 229960003767 alanine Drugs 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 13
- 230000035899 viability Effects 0.000 claims description 12
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 210000002421 cell wall Anatomy 0.000 claims description 10
- 101150033534 lysA gene Proteins 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 9
- 229930182847 D-glutamic acid Natural products 0.000 claims description 8
- 108091029865 Exogenous DNA Proteins 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 101150014717 LysP gene Proteins 0.000 claims description 5
- 101100327514 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) cfbE gene Proteins 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 101150093075 murD gene Proteins 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000004075 alteration Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 101150072105 hok gene Proteins 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Substances 0.000 claims 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000004260 plant-type cell wall biogenesis Effects 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 14
- 230000004048 modification Effects 0.000 abstract description 7
- 238000012986 modification Methods 0.000 abstract description 7
- 108020004999 messenger RNA Proteins 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 239000013615 primer Substances 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 21
- 101150102398 Galt gene Proteins 0.000 description 20
- 101150002054 galE gene Proteins 0.000 description 19
- 238000001415 gene therapy Methods 0.000 description 19
- 101150043597 murE gene Proteins 0.000 description 18
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 16
- 230000037430 deletion Effects 0.000 description 15
- 238000012217 deletion Methods 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 13
- 108010013639 Peptidoglycan Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 101100245742 Campylobacter jejuni subsp. jejuni serotype O:23/36 (strain 81-176) pseB gene Proteins 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 229940113082 thymine Drugs 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000002427 irreversible effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 101150108069 murE1 gene Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 4
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 4
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000003578 bacterial chromosome Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 101150048892 parB gene Proteins 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010041525 Alanine racemase Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 101100292867 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) murE gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 101710126486 Envelope glycoprotein D Proteins 0.000 description 3
- 101710126496 Envelope glycoprotein I Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 101150038355 murE2 gene Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102100039558 Galectin-3 Human genes 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 108091033454 Hok/sok system Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 101150101241 hokA gene Proteins 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- HOSWPDPVFBCLSY-UHFFFAOYSA-N 2-azaniumyl-4-oxobutanoate Chemical compound OC(=O)C(N)CC=O HOSWPDPVFBCLSY-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000135860 Capparis spinosa subsp spinosa Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001068914 Melicope knudsenii Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 101150107204 asd gene Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220219006 rs1060501597 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54805995A | 1995-10-17 | 1995-10-17 | |
| US08/548,059 | 1995-10-17 | ||
| US56497395A | 1995-11-30 | 1995-11-30 | |
| US08/564,973 | 1995-11-30 | ||
| PCT/CA1996/000693 WO1997014805A2 (en) | 1995-10-17 | 1996-10-17 | Methods for production of recombinant plasmids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11513562A true JPH11513562A (ja) | 1999-11-24 |
| JPH11513562A5 JPH11513562A5 (enExample) | 2004-10-14 |
Family
ID=27068752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9515377A Ceased JPH11513562A (ja) | 1995-10-17 | 1996-10-17 | 組換えプラスミドの生産方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5922583A (enExample) |
| EP (1) | EP0856059B1 (enExample) |
| JP (1) | JPH11513562A (enExample) |
| AT (1) | ATE247713T1 (enExample) |
| AU (1) | AU7208896A (enExample) |
| CA (1) | CA2232234A1 (enExample) |
| DE (1) | DE69629576T2 (enExample) |
| TW (1) | TW514667B (enExample) |
| WO (1) | WO1997014805A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007511236A (ja) * | 2003-11-20 | 2007-05-10 | コブラ バイオロジックス リミテッド | プラスミドの維持 |
| JP2008512998A (ja) * | 2004-09-17 | 2008-05-01 | ベーリンガー インゲルハイム オーストリア ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗生物質フリーのＣｏ１Ｅ１プラスミドを増殖するための宿主ベクター系 |
| JP2014064579A (ja) * | 2001-02-23 | 2014-04-17 | Universite Libre De Bruxelles | 毒性分子に対する抗毒性蛋白質をコードする配列を含む組換体クローンの選択方法 |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1006085A3 (fr) * | 1992-07-31 | 1994-05-10 | Univ Bruxelles | Vecteur de clonage. |
| WO1999058652A2 (en) * | 1998-05-07 | 1999-11-18 | Gx Biosystems A/S | Cytotoxin-based biological containment |
| WO2000028048A1 (en) * | 1998-11-09 | 2000-05-18 | Genecare Development Aps | Novel plasmids for use in medicine and method of producing same |
| US8076130B2 (en) * | 1998-12-02 | 2011-12-13 | University Of Maryland, Baltimore | Plasmid maintenance system for antigen delivery |
| US6413768B1 (en) | 1998-12-02 | 2002-07-02 | University Of Maryland | Expression plasmids |
| JP2003506007A (ja) | 1998-12-02 | 2003-02-18 | ユニヴァーシティ オブ メリーランド，ボルチモア | 抗原送達用プラスミド維持系 |
| US6423545B1 (en) * | 1999-07-08 | 2002-07-23 | Albert Einstein College Of Medicine Of Yeshiva University | Unmarked deletion mutants of mycobacteria and methods of using same |
| EP1111061A1 (en) * | 1999-12-20 | 2001-06-27 | Universite Libre De Bruxelles | Double selection vector |
| US9012141B2 (en) * | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| US7396822B2 (en) * | 2001-05-24 | 2008-07-08 | Vaxiion Therapeutics, Inc. | Immunogenic minicells and methods of use |
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20030224444A1 (en) * | 2002-02-25 | 2003-12-04 | Sabbadini Roger A. | Antibodies to native conformations of membrane proteins |
| US20030224369A1 (en) * | 2002-02-25 | 2003-12-04 | Surber Mark W. | Reverse screening and target identification with minicells |
| US20030207833A1 (en) * | 2002-02-25 | 2003-11-06 | Neil Berkley | Pharmaceutical compositions with minicells |
| CA2477194A1 (en) * | 2002-03-19 | 2003-09-25 | Universite Libre De Bruxelles | Poison/antidote genetic systems for the selection of genetically modified eucaryote cells or organisms |
| US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
| AU2003260200A1 (en) * | 2002-09-03 | 2004-03-29 | Universite Libre De Bruxelles | Reversible, parallel and multitask cloning method and kit |
| US9309518B2 (en) | 2002-09-03 | 2016-04-12 | Universite Libre De Bruxelles | Reversible, parallel and multitask cloning method and kit |
| WO2006055024A2 (en) * | 2004-04-05 | 2006-05-26 | Vaxiion Therapeutics, Inc. | Minicells as vaccines |
| ES2684749T3 (es) * | 2004-08-13 | 2018-10-04 | The Trustees Of The University Of Pennsylvania | Métodos para construir vacunas sin resistencia a antibióticos |
| CN1912127B (zh) * | 2005-08-08 | 2011-05-25 | 百瑞全球有限公司 | 一种大肠杆菌表达载体及其应用 |
| EP2152889B1 (en) | 2007-05-29 | 2017-03-15 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| ES2741730T3 (es) * | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
| US20120135033A1 (en) * | 2008-05-19 | 2012-05-31 | Anu Wallecha | Multiple delivery system for heterologous antigens |
| EP2498808A4 (en) * | 2009-11-11 | 2014-01-08 | Advaxis | COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| US10005820B2 (en) | 2011-02-15 | 2018-06-26 | Vaxiion Therapeutics, Llc | Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| EP2825195A4 (en) | 2012-03-12 | 2015-10-07 | Advaxis Inc | INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE |
| EP2890404B1 (en) | 2012-08-29 | 2018-06-13 | Nature Technology Corporation | Dna plasmids with improved expression |
| WO2014077863A1 (en) | 2012-11-19 | 2014-05-22 | Nature Technology Corporation | Replicative minicircle vectors with improved expression |
| BR122021015417B1 (pt) | 2013-08-19 | 2022-11-08 | Syngulon Sa | Célula microbiana geneticamente engenheirada que compreende um ácido nucleico que codifica uma bacteriocina |
| WO2019057774A1 (en) | 2017-09-19 | 2019-03-28 | Deutsches Krebsforschungszentrum | NON-INTEGRATING DNA VECTORS FOR THE GENETIC MODIFICATION OF CELLS |
| DK3456821T4 (da) | 2017-09-19 | 2024-04-15 | Deutsches Krebsforsch | Ikke-integrerende dna-vektorer til genetisk modifikation af celler |
| CN111757890A (zh) | 2017-12-19 | 2020-10-09 | 辛格隆股份公司 | 发酵工艺 |
| JP7520719B2 (ja) | 2018-03-21 | 2024-07-23 | アルデブロン，エル．エル．シー． | 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター |
| WO2025160245A1 (en) | 2024-01-25 | 2025-07-31 | Aldevron, L.L.C. | Viral and non-viral nanoplasmid vectors with improved production |
| WO2025231315A2 (en) | 2024-05-03 | 2025-11-06 | Aldevron, L.L.C. | Bacterial host strains |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968619A (en) * | 1976-09-27 | 1990-11-06 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4190495A (en) * | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
| US5077044A (en) * | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4550081A (en) * | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
| US5210035A (en) * | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
| US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
| DK410783D0 (da) * | 1982-09-16 | 1983-09-09 | Benzon A Salfred | Fremgangsmade til stabilisering af plasmider |
| US5702916A (en) * | 1982-09-16 | 1997-12-30 | Gx Biosystems A/S | Biological Containment |
| FR2568891B1 (fr) * | 1984-08-09 | 1988-05-27 | Transgene Sa | Procede de preparation d'une souche, notamment de levure, transformee par un vecteur d'expression, qui peut etre cultivee sur un milieu complet sans pression de selection et souche ainsi obtenue |
| DK594084A (da) * | 1984-12-12 | 1986-06-13 | Novo Industri As | Fremgangsmaade til stabilisering af extra-chromosomale elementer i bakterier under dyrkning |
| GB2177097A (en) * | 1985-06-18 | 1987-01-14 | Genencor Inc | Stable maintenance of nucleic acid in recombinant cells |
| DK275685D0 (da) * | 1985-06-18 | 1985-06-18 | Benzon As Alfred | Stabilisering af biologiske systemer |
| US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| IL86583A0 (en) * | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| ATE121785T1 (de) * | 1987-10-07 | 1995-05-15 | Univ Washington | Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation. |
| IL91525A0 (en) * | 1988-09-06 | 1990-04-29 | Univ Washington | Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof |
| AU5355990A (en) * | 1989-03-31 | 1990-11-05 | Washington University | Avirulent microbes and uses therefor |
| AU645489B2 (en) * | 1989-03-31 | 1994-01-20 | Washington University | Vaccines containing avirulent phoP-type microorganisms |
| EP0474646A4 (en) * | 1989-03-31 | 1992-10-21 | Washington University | Bordetella vaccines |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU6737190A (en) * | 1989-11-03 | 1991-05-31 | Washington University | Cross-protective salmonella vaccines |
| DE69131014T2 (de) * | 1990-11-21 | 1999-10-07 | Washington University, St. Louis | Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe |
| AU6705594A (en) * | 1993-04-15 | 1994-11-08 | Washington University | Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation |
-
1996
- 1996-10-16 US US08/732,612 patent/US5922583A/en not_active Expired - Fee Related
- 1996-10-17 CA CA002232234A patent/CA2232234A1/en not_active Abandoned
- 1996-10-17 DE DE69629576T patent/DE69629576T2/de not_active Expired - Fee Related
- 1996-10-17 AT AT96933294T patent/ATE247713T1/de not_active IP Right Cessation
- 1996-10-17 JP JP9515377A patent/JPH11513562A/ja not_active Ceased
- 1996-10-17 WO PCT/CA1996/000693 patent/WO1997014805A2/en not_active Ceased
- 1996-10-17 EP EP96933294A patent/EP0856059B1/en not_active Expired - Lifetime
- 1996-10-17 AU AU72088/96A patent/AU7208896A/en not_active Abandoned
- 1996-12-24 TW TW085115998A patent/TW514667B/zh not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014064579A (ja) * | 2001-02-23 | 2014-04-17 | Universite Libre De Bruxelles | 毒性分子に対する抗毒性蛋白質をコードする配列を含む組換体クローンの選択方法 |
| JP2007511236A (ja) * | 2003-11-20 | 2007-05-10 | コブラ バイオロジックス リミテッド | プラスミドの維持 |
| JP2008512998A (ja) * | 2004-09-17 | 2008-05-01 | ベーリンガー インゲルハイム オーストリア ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗生物質フリーのＣｏ１Ｅ１プラスミドを増殖するための宿主ベクター系 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE247713T1 (de) | 2003-09-15 |
| TW514667B (en) | 2002-12-21 |
| WO1997014805A3 (en) | 1997-06-12 |
| DE69629576T2 (de) | 2004-06-24 |
| US5922583A (en) | 1999-07-13 |
| EP0856059B1 (en) | 2003-08-20 |
| DE69629576D1 (de) | 2003-09-25 |
| WO1997014805A2 (en) | 1997-04-24 |
| CA2232234A1 (en) | 1997-04-24 |
| EP0856059A1 (en) | 1998-08-05 |
| AU7208896A (en) | 1997-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH11513562A (ja) | 組換えプラスミドの生産方法 | |
| US20040106118A1 (en) | Method for exposing peptides and polypeptides on the cell surface of bacteria | |
| JP3976685B2 (ja) | タンパク質分泌のためのＣｌｙＡ溶血素の使用 | |
| JPH07506240A (ja) | コレラトキシンの免疫原性無毒化変異体およびトキシンｌｔの免疫原性無毒化変異体，それらの調製，ならびにワクチンの調製のためのそれらの使用 | |
| JPH11235191A (ja) | 細胞の遺伝的集団において所望の組換え遺伝子を維持する方法 | |
| JPH07278195A (ja) | 組み換えｇ−ｃｓｆ | |
| JPH0138475B2 (enExample) | ||
| JPH0376580A (ja) | 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法 | |
| JPH05192161A (ja) | 安定ｐｕｒＡベクターおよびそれらの使用 | |
| US20110129487A1 (en) | Plasmic production and expression of recombinant proteins in cells grown without antibiotics | |
| EP3735268A1 (en) | Auxotrophic strains of staphylococcus bacterium | |
| Wang et al. | Bacillus subtilis RNase III gene: cloning, function of the gene in Escherichia coli, and construction of Bacillus subtilis strains with altered rnc loci | |
| WO1994000463A2 (en) | Production of hyaluronic acid by transeformed microorganisms | |
| CN118497176B (zh) | 一种免疫球蛋白降解酶 | |
| JP3620831B2 (ja) | 乳酸菌シャトルベクター | |
| CN115873852A (zh) | 重组核酸序列、基因工程菌及生产1,5-戊二胺的方法 | |
| US20050153398A1 (en) | Flavobacterium heparinum expression system | |
| US7049097B2 (en) | Antibiotics-independent vector for constant high-expression and method for gene expression using the same | |
| CN100359001C (zh) | 宿主细胞中重组多肽的区室化 | |
| Engel et al. | Enzymatic preparation of 1, 6-anhydro-muropeptides by immobilized murein hydrolases from Escherichia coli fused to staphylococcal protein A | |
| US20040175705A1 (en) | Systems for expression of heterologous proteins in m capsulatus | |
| KR100434108B1 (ko) | L-트립토판의유전공학적제조방법 | |
| JPS58501406A (ja) | エシエリヒア・コリ−における蛋白合成発現の高揚 | |
| JP2004519239A (ja) | タンパク質発現のための調節領域を含むｄｎａ配列 | |
| JP2025536332A (ja) | 細胞外膜リポタンパク質ＰｒｓＡ発現系を用いた細胞表面大量発現技術 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060530 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20061016 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061121 |